Similar articles for PMID: 20004954

Year	Number of Results
1982	1
1983	1
1995	3
1996	1
1998	1
1999	1
2004	2
2005	3
2006	9
2007	11
2008	8
2009	9
2010	21
2011	15
2012	12
2013	7
2014	8
2015	11
2016	13
2017	9
2018	4
2019	5
2020	5
2021	7
2022	1
2024	0

1

Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.

Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP. Daoussis D, et al. Semin Arthritis Rheum. 2010 Oct;40(2):127-36. doi: 10.1016/j.semarthrit.2009.09.003. Epub 2009 Dec 11. Semin Arthritis Rheum. 2010. PMID: 20004954 Review.

2

B cells in systemic sclerosis: a possible target for therapy.

Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G. Bosello S, et al. Autoimmun Rev. 2011 Aug;10(10):624-30. doi: 10.1016/j.autrev.2011.04.013. Epub 2011 Apr 22. Autoimmun Rev. 2011. PMID: 21545850 Review.

3

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.

Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; EUSTAR Rituximab study group. Jordan S, et al. Ann Rheum Dis. 2015 Jun;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522. Epub 2014 Jan 17. Ann Rheum Dis. 2015. PMID: 24442885

4

B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.

Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis SN. Daoussis D, et al. Arthritis Res Ther. 2016 May 21;18(1):118. doi: 10.1186/s13075-016-1017-y. Arthritis Res Ther. 2016. PMID: 27208972 Free PMC article. Clinical Trial.

5

Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?

Simms RW, Lafyatis R. Simms RW, et al. Rheumatology (Oxford). 2010 Feb;49(2):201-2. doi: 10.1093/rheumatology/kep421. Epub 2009 Dec 23. Rheumatology (Oxford). 2010. PMID: 20032221 No abstract available.

6

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.

Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis SN. Daoussis D, et al. Semin Arthritis Rheum. 2017 Apr;46(5):625-631. doi: 10.1016/j.semarthrit.2016.10.003. Epub 2016 Oct 13. Semin Arthritis Rheum. 2017. PMID: 27839742

7

New developments in the pathogenesis of systemic sclerosis.

Sakkas LI. Sakkas LI. Autoimmunity. 2005 Mar;38(2):113-6. doi: 10.1080/16066350500095415. Autoimmunity. 2005. PMID: 16040330 Review.

8

B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.

Hasegawa M. Hasegawa M. J Dermatol. 2010 Jan;37(1):3-10. doi: 10.1111/j.1346-8138.2009.00763.x. J Dermatol. 2010. PMID: 20175836 Review.

9

Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.

Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Giuggioli D, et al. Autoimmun Rev. 2015 Nov;14(11):1072-8. doi: 10.1016/j.autrev.2015.07.008. Epub 2015 Jul 22. Autoimmun Rev. 2015. PMID: 26209905 Review.

10

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Daoussis D, et al. Rheumatology (Oxford). 2010 Feb;49(2):271-80. doi: 10.1093/rheumatology/kep093. Epub 2009 May 15. Rheumatology (Oxford). 2010. PMID: 19447770 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

141 results

Results by year